Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers
Abstract
The impact of checkpoint inhibitors on gastroesophageal cancer treatment has been tremendous in the last 2 years. KEYNOTE-590, CHECKMATE 649 and CheckMate 648 are landmark trials that have introduced immunotherapy to the field as first-line therapy, leading to a paradigm change for advanced esophageal and gastric cancer. Chemotherapy in combination with immunotherapy is now the standard of care for first-line treatment of locally advanced or metastatic adenocarcinoma of the esophagus, esophagogastric junction and stomach. Several new targets and treatments are available for gastroesophageal cancer that are based on the characterization of cancer cells and the tumor microenvironment. Biomarker-based therapy selection is critical to optimize outcomes and minimize toxicities, as well as give insight into the optimal timing and sequence of a patient's treatment course.
Plain language summary
Doctors have found a better treatment for advanced esophageal and stomach cancer. They combined two types of medicines called immune checkpoint inhibitors and chemotherapy. This made more people respond to the treatment and live longer without the cancer getting worse. They use a test called PD-L1 Combined Positive Score to see if the treatment will work but, when looking at the results, there remain challenges and new treatments and tests are still needed for these cancers.
Papers of special note have been highlighted as: •• of considerable interest
References
- 1. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8(8), (2017).
- 2. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World J. Gastrointest. Oncol. 9(8), 333–340 (2017).
- 3. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14(6), 490–499 (2013).
- 4. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18(11), 1467–1482 (2017).
- 5. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 3(5), 620–627 (2017).
- 6. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 20(3), 420–435 (2019).
- 7. . The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J. Gastrointest. Oncol. 7(5), 771–788 (2016).
- 8. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol. Res. Pract. 216(4), 152881 (2020).
- 9. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res. 26(24), 6453–6463 (2020).
- 10. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann. Oncol. 30(7), 1096–1103 (2019).
- 11. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).
- 12. . The Cancer Genome Atlas: creating lasting value beyond its data. Cell 173(2), 283–285 (2018).
- 13. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014).
- 14. . Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat. Rev. Clin. Oncol. 18(8), 473–487 (2021).
- 15. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer 20(3), 407–415 (2017).
- 16. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8(1), 49–58 (2018).
- 17. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24(9), 1449–1458 (2018).
- 18. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 11(9), 2168–2185 (2021).
- 19. DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden. Cell Rep. Med. 1(3), 100034(2020).
- 20. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398(10302), 759–771 (2021). •• This study ultimately resulted in the US FDA approval of pembrolizumab in addition to chemotherapy for the first-line treatment of esophageal cancer.
- 21. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. J. Clin. Oncol. 40(Suppl. 4), 241 (2022).
- 22. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J. Clin. Oncol. 39(Suppl. 18), LBA4001 (2021).
- 23. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386(5), 449–462 (2022). •• First-line treatment of advanced esophageal squamous cell carcinoma with either nivolumab plus chemotherapy or nivolumab plus ipilimumab resulted in a significant overall survival benefit.
- 24. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10), 916–925 (2021).
- 25. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 377, e068714 (2022).
- 26. 1373MO JUPITER-06: a randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ann. Oncol. 32, S1041 (2021).
- 27. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study. Ann. Oncol. 32, S1330 (2021).
- 28. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294), 27–40 (2021). •• Checkmate 649 was a pivotal trial that resulted in US FDA approval of nivolumab for advanced esophagogastric adenocarcinoma.
- 29. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy, safety, and subgroup analyses from CheckMate 649. J. Clin. Oncol. 40(Suppl. 4), 240 (2022).
- 30. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J. Clin. Oncol. 40(4), 392–402 (2022).
- 31. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann. Oncol. 32, S1331 (2021).
- 32. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann. Oncol. 30(2), 250–258 (2019).
- 33. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann. Oncol. 31, S1192 (2020).
- 34. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6(10), 1571–1580 (2020).
- 35. Association of tumor mutational burden with efficacy of pembrolizumab ± chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin. Cancer Res. 28(16), 3489–3498 (2022).
- 36. VP1-2023: pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: phase III KEYNOTE-859 study. Ann. Oncol. 34(3), 319–320 (2023).
- 37. The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions. Cancer Immunol. Immunother. 67(7), 1079–1090 (2018).
- 38. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).J. Clin. Oncol. 41(Suppl. 4), 286 (2023).
- 39. Esophageal and Esophagogastric Junction Cancers, version 4.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw 17(7), 855–883 (2021).
- 40. Gastric Cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 20(2), 167–192 (2022).
- 41. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3), 476–484 (2015).
- 42. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).
- 43. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer 22(3), 527–535 (2019).
- 44. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study. Clin. Cancer Res. 24(5), 1082–1089 (2018).
- 45. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J. Clin. Invest. 124(12), 5145–5158 (2014).
- 46. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 21(6), 821–831 (2020).
- 47. Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer. Clin. Cancer Res. 22(13), 3249–3259 (2016).
- 48. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13(17), 5133–5143 (2007).
- 49. . Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12(4), 237–251 (2012).
- 50. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer. Cancer Discov. 12(4), 984–1001 (2022).
- 51. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial. JAMA Oncol. 8(8), 1150–1158 (2022).
- 52. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study. J. Clin. Oncol. 39(Suppl. 15), 4013 (2021).
- 53. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382(25), 2419–2430 (2020).
- 54. . Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 111(12), 4636–4645 (2020).
- 55. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 13(6), R123 (2011).
- 56. Margetuximab mediates greater Fc-dependent anti-tumor activities than trastuzumab or pertuzumab in vitro. Cancer Res. 79(Suppl. 13), 1538 (2019).
- 57. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 21(8), 1066–1076 (2020).
- 58. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): results from a phase I study. J. Clin. Oncol. 39(Suppl. 3), 164 (2021).
- 59. 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA). Ann. Oncol. 32, S1044–S1045 (2021).
- 60. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLOS ONE 13(8), e0201832 (2018).
- 61. SO-31 ASPEN-01: a phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Ann. Oncol. 32, S215–S216 (2021).
- 62. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15(11), 1224–1235 (2014).
- 63. 525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. Ann. Oncol. 31, S462–S463 (2020).
- 64. Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer-results from phase Ib trial IMU.ACS.001. Clin. Cancer Res. 27(13), 3649–3660 (2021).
- 65. HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma–overall survival analysis. J. Clin Oncol. 41(Suppl. 4), 289 (2023).
- 66. A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data. J Immunother Cancer. 9(Suppl. 2), A1–A1054 (2021).
- 67. . Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22(11), 1342–1350 (2016).
- 68. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4(5), e180013 (2018).
- 69. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142), 123–133 (2018).
- 70. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 7(6), 895–902 (2021).
- 71. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. J. Clin. Oncol. 41(Suppl. 4), 290 (2023).
- 72. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): a phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 11(2), 308–325 (2021).
- 73. . The potential role of immunotherapy to treat colorectal cancer. Exp. Opin. Investig. Drugs 24(3), 329–344 (2015).
- 74. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111), 2461–2471 (2017).
- 75. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29(10), 2052–2060 (2018).
- 76. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31(34), 4311–4318 (2013).
- 77. . Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74–88 (2013).
- 78. . Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front. Immunol. 10, 1654 (2019).
- 79. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. Clin. Cancer Res. 26(4), 846–854 (2020).
- 80. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): checkMate 649 study. Ann. Oncol. 32, S1329–S1330 (2021).
- 81. CheckMate-032 Study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36(28), 2836–2844 (2018).
- 82. . Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J. Clin. Invest. 128(8), 3209–3218 (2018).
- 83. LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Ann. Oncol. 32, S227–S228 (2021).
- 84. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells. Cancer Discov. 11(5), 1100–1117 (2021).
- 85. A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer. J. Clin. Oncol. 40(Suppl. 4), 308 (2022).
- 86. . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15(5), 325–340 (2018).
- 87. Ramucirumab in combination with pembrolizumab in treatment-naïve advanced gastric or GEJ adenocarcinoma: safety and antitumor activity from the phase 1a/b JVDF trial. Cancers (Basel) 12(10), 2985(2020).
- 88. Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study). J. Clin. Oncol. 37(Suppl. 4), 129 (2019).
- 89. Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D). J. Clin. Oncol. 36(Suppl. 4), 92 (2018).
- 90. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin. Cancer Res. 27(4), 1029–1036 (2021).
- 91. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38(18), 2053–2061 (2020).
- 92. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 21(8), 1057–1065 (2020).
- 93. A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. J. Clin. Oncol. 40(Suppl. 4), TPS369 (2022).
- 94. First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): safety run-in results. J. Clin. Oncol. 41(Suppl. 4), 411 (2023).
- 95. Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study). J. Clin. Oncol. 41(Suppl. 4), 396 (2023).
- 96. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14(23), 7624–7634 (2008).
- 97. . Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J. Hematol. Oncol. 10(1), 105 (2017).
- 98. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30(9), 1487–1495 (2019).
- 99. Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18. 2+/HER2-advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study. J. Clin. Oncol. 40(Suppl. 4), TPS365 (2022).
- 100. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28(6), 1189–1198 (2022).
- 101. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). J. Clin. Oncol. 39(Suppl. 3), 160 (2021).